Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. reports a year-on-year increase in operational loss to $17,661,714 due to higher consulting and R&D expenditure, despite not declaring any dividends and receiving significant government grants and rebates. The company made considerable progress in its anti-infective program, with RECCE® 327 gaining WHO recognition, patent approvals, and positive clinical trial results, including successful treatment of diabetic foot infections and advancements in their burn wound program.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
